Is there Evidence for a Continued Benefit for Long‐Term Lecanemab Treatment? A Benefit/Risk Update from Long‐Term Efficacy, Safety and Biomarker Data
van Dyck C, Sperling R, Dhadda S, Li D, Hersch S, Irizarry M, Kramer L. Is there Evidence for a Continued Benefit for Long‐Term Lecanemab Treatment? A Benefit/Risk Update from Long‐Term Efficacy, Safety and Biomarker Data. Alzheimer's & Dementia 2024, 20: e092094. PMCID: PMC11713166, DOI: 10.1002/alz.092094.Peer-Reviewed Original ResearchOpen-label extensionAlzheimer's diseaseBrain regions of individualsMultiple measures of cognitionMeasures of cognitionAmyloid-betaTau spreadingMarkers of amyloidAD studiesRegions of individualsBrain regionsHuman IgG1 monoclonal antibodyPhase 2 studyMonths of treatmentLong-term efficacyLecanemabLonger-term dosingIgG1 monoclonal antibodyInfusion reactionsMultiple measuresRandomized studyCT1812 biomarker signature from a meta‐analysis of CSF proteomic findings from two Phase 2 clinical trials in Alzheimer's disease
Lizama B, Williams C, North H, Pandey K, Duong D, Di V, Mecca A, Blennow K, Zetterberg H, Levey A, Grundman M, van Dyck C, Caggiano A, Seyfried N, Hamby M. CT1812 biomarker signature from a meta‐analysis of CSF proteomic findings from two Phase 2 clinical trials in Alzheimer's disease. Alzheimer's & Dementia 2024, 20: 6860-6880. PMID: 39166791, PMCID: PMC11485314, DOI: 10.1002/alz.14152.Peer-Reviewed Original ResearchVolumetric magnetic resonance imagingMagnetic resonance imagingPharmacodynamic biomarkersMeta-analysisClinical developmentCerebrospinal fluidPhase 2 clinical trialResonance imagingAlzheimer's diseaseMechanism of actionClinical trialsTandem mass tag-mass spectrometryClinical cohortMild to moderate ADCandidate biomarkersCT1812CohortBiomarker signaturesBiomarkersProteomic findingsUnbiased analysisNetwork analysisAmyloid-betaSynaptic biologyBiological impact
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply